Advertising a Research Reagent in the UK: The CAP Code Line Between Description and Claim

The Advertising Standards Authority does not regulate what a research reagent is. It regulates what is said about it. The UK Code of Non-broadcast Advertising and Direct & Promotional Marketing — the CAP Code, which the ASA enforces — requires documentary evidence for any claim a reader would take as objective, held before the claim is published ^[1], and it forbids medicinal claims for anything that is not a licensed medicine ^[2].

This is a description of the rules and of the rulings that show where the line falls, written for somebody reading a supplier's pages rather than writing them. It is not a copywriting guide and suggests no wording. The medicines-law side of the same boundary — when presentation makes a product a medicine — is the subject of the MHRA's April 2026 inquiry covered in the pillar of this cluster.

Two regulators, one boundary

The ASA enforces an advertising code; the MHRA enforces medicines law. They meet at medicinal claims. Rule 12.11 of the CAP Code says medicines must have a licence from the MHRA, the VMD or under the auspices of the EMA before they are marketed ^[2]. Whether something is a medicine is decided by the medicines definition — presentation or function — which the MHRA applies ^[5]. The Code is not confined to paid ads: it applies to claims on a marketer's own website and in other non-paid-for space online under its control, such as its social media accounts, where they are directly connected with the supply of goods ^[7].

ASA rulings borrow that definition directly. In its July 2026 ruling on Kind Patches Ltd, the ASA said that because the ad's claims implied the product had medicinal properties, it was a medicinal product by presentation for the purposes of the medicines legislation reflected in the Code, and the advertiser did not hold the necessary authorisation ^[4]. One test, applied by two bodies with different sanctions.

The rules that matter

The misleading-advertising rules in section 3 apply to every product ^[1]. Section 12 adds the health-specific layer, including the requirement in rule 12.1 that objective claims be backed by evidence which, where relevant, consists of trials conducted on people ^[2]. For a research reagent that last requirement is rarely a question of how good the evidence is: a reagent supplied for laboratory work has no such evidence, and it is not in a position to make the claim at all.

Substantiation: "tested" and "pure" are claims

Rule 3.7 is short and demanding. Before a marketing communication is published, the marketer must hold documentary evidence to prove claims consumers are likely to regard as objective ^[1]. The evidence has to exist first. Assembling it after somebody complains is too late.

Most of what a research reagent's page says is objective in this sense. A purity percentage is a measurable statement; its evidence is an analytical report for the batch actually being sold. "Third-party tested" is a claim about who did the testing; its evidence is a report issued by that party. "Lab tested" with no qualifier invites three questions — which laboratory, which test, which batch — and the claim is only as good as the answers.

• A purity figure: a batch-specific analytical report showing that figure, for that lot ^[1].
• An identity statement: an analytical result that confirms identity, not only a purity trace.
• "Independently tested": a report from a laboratory that is in fact independent of the seller.
• An accreditation mark: an accreditation whose scope covers the test being referred to.
• Any statement about sterility or endotoxin: a result for that test, which a routine purity report does not contain.

From the buyer's chair this is a quality signal as much as a compliance point. An objective claim with no document behind it when asked is a claim the seller could not substantiate under the Code, and a seller who makes unsupported objective claims has told you how they treat evidence generally.

Medicinal claims: the line an unlicensed product cannot cross

Rule 12.6 prohibits false claims that a product can prevent or treat disease, or restore, correct or modify a physiological function ^[2]. Rule 12.11 goes further for anything unlicensed: medicinal claims cannot be made for it however good the evidence might be, because the product is not a licensed medicine ^[2].

The ASA's May 2025 ruling on Viva Research Ltd, concerning paid social ads for a supplement, states the principle plainly: claims that a product had medicinal properties may only be made for a licensed medicinal product. The complaint was upheld on every point ^[3].

The Kind Patches ruling of 15 July 2026 shows how little it takes. A paid social ad for a patch named after a class of prescription medicine, with claims about cravings and fullness, was read by the ASA as presenting the product as equivalent to prescription-only injections used for weight management. That made it a medicinal product by presentation without authorisation, in breach of rules 12.1 and 12.11 among others ^[4]. The product name did much of the work.

The MHRA's guidance lists the same features as tending to make a product a medicine: references to medical conditions, comparison with licensed medicines, product names that refer to medical conditions, references to clinical research and testing, recommendations by health professionals, and testimonials that include or imply medicinal claims ^[5].

Why a research label does not work as a disclaimer

The ASA judges an ad by the impression it creates as a whole. In the Viva Research ruling the advertiser argued that lines denying its product was a prescription drug were there to make clear it was not a medicine; the ASA found that, in context, those lines supported the reading that the product could address the symptoms the drug treats ^[3]. A denial placed beside an implied claim can strengthen the claim.

The medicines side takes the same view. The MHRA's guidance records that a statement that a product is not medicinal is persuasive evidence a court may take into consideration, but is not in itself conclusive ^[5]. "Research use only" is a statement of that kind. It is accurate and useful where everything around it is consistent with it. Placed beside benefit language, it is a contradiction rather than a defence — which is unsurprising once you recall that "research chemical" is a trade phrase rather than a legal category and confers nothing by being printed.

Testimonials and reviews

Rule 3.47 requires marketers to hold documentary evidence that a testimonial is genuine, and rule 3.45 requires incentivised reviews to be identified as such ^[1]. Those are the procedural rules. The substantive problem is different.

A review describing what a product did for the reviewer is a claim, and a seller who publishes it on a product page has adopted it. The MHRA guidance lists testimonials that include or imply medicinal claims among the features it takes into account when deciding whether a product is presented as a medicine ^[5]. A seller can write nothing but chemistry and still end up with a page full of claims it cannot make, supplied by its customers.

The prescription-only ban

Rule 12.12 is absolute: prescription-only medicines and prescription-only medical treatments may not be advertised to the public ^[2]. The ASA has enforced it at scale. Its enforcement report of 2 April 2026 describes capturing more than 95,000 paid online ads from 44 advertisers, of which around 900 from 38 advertisers were assessed as likely to break the rules by promoting prescription-only medicines for weight management; the rate of likely breaches fell from 7% when monitoring began in February 2025 to 1% after a second enforcement notice, with 99% compliance reported by January 2026 ^[6].

For research reagents the relevance is indirect but real. Naming or comparing with a prescription medicine to sell something that is not one runs into rule 12.12 and rule 12.11 at once, as the Kind Patches ruling shows ^[4].

Reading a supplier's pages against the Code

None of this requires you to adjudicate. It gives you a structured way to read what a supplier publishes, because the features the ASA and the MHRA look for are the same features that tell you how carefully a supplier operates.

1. Every figure on the page has a batch-specific document behind it, supplied on request ^[1].
2. No statement anywhere — product page, FAQ, blog, social account, reviews — describes an effect in a person ^{[2] [5]}.
3. No prescription medicine is named or compared with as a selling point ^{[2] [4]}.
4. Research status is stated consistently in the product documentation, not only in a footer.
5. Testing claims say who tested what, and which batch.

ASA rulings are published and searchable on the ASA's own site. A seller's history there, or the absence of one, is public information, and it is a better guide than a seller's own account of its compliance.